MOSAIC Therapeutics is awarded funding from Innovate UK to use whole-genome sequencing data to identify synthetic-lethal targets in colon and oesophageal cancer.
The IUK award will also be used towards company formation, the setting in place of key operations, and the formation of strategic alliances with biopharma partners. These activities will yield MOSAIC’s first targets, help the development of an operational team, and support the business planning, deeper market awareness and venture capital engagement necessary to progress the company.
More information about the MOSAIC Dual Technology Platform is available here.
We are a cancer therapeutics company using advanced computational methods and next-generation cancer models to find new synthetic-lethal cancer targets. Our main mission is to tackle cancers with substantial unmet need by reinventing target discovery. We have active programmes across a variety of cancer indications and disease biology fields and we are seeking strategic alliances with pharma companies who wish to leverage our world-leading data and platforms.
Born out of pioneering research at the Wellcome Sanger Institute and anchored around a proprietary database that has seen 20 years of tuning and development, our tools and know-how will provide our partners with an unparalleled complement of world-leading capabilities.
For media and editorial enquiries, please email: email@example.com